Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 ...

According to Priovant, the Phase 2 BEACON study is the first industry-sponsored placebo-controlled trial in cutaneous sarcoidosis to deliver positive data.

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 ...

Shares of Roivant Sciences were higher after the company released positive results from a phase-two study of its brepocitinib treatment for cutaneous sarcoidosis, a skin disease. The stock rose 14% to ...

Sarcoidosis is a multi-systemic disease of unknown etiology with a clinical presentation ranging from asymptomatic disease to organ failure. While some patients with sarcoidosis have spontaneous ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with the JAK inhibitor tofacitinib saw a dose-dependent response in the treatment of cutaneous ...

Nothing about sarcoidosis is easy. First identified in 1877, it is quite common. In the United States, lifetime risk is 2.4% and 0.85% for African American persons and White persons, respectively.

Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Steroids alone was the most common treatment for the ...

The Foundation for Sarcoidosis Research (FSR) has awarded four grants in the amount of $100,000 each to Dr. Christen Vagts from the University of Illinois at Chicago, Dr. Chieh-Yu Lin from Washington ...

Muscular sarcoidosis is a rare disease characterised by non-caseating granulomas in muscle tissue. We report a woman in her late 70s with progressive lower-limb weakness, in whom ultrasonography ...

CHICAGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) has awarded four grants in the amount of $100,000 each to Dr. Christen Vagts from the University of Illinois at ...